Multiple Sclerosis affects millions worldwide with diverse symptoms; early diagnosis, multidisciplinary care, and awareness ...

The objective of this investigation was to examine treatment persistence with glatiramer acetate (GA) relative to available disease-modifying therapies (DMT) for multiple sclerosis (MS ...

Using disease-modifying therapies in MS tends to reduce the risk of stroke, though effects vary depending on the type of DMT, ...

Zydus’ generic Glatiramer Acetate Injection is an FDA-approved ... 40 mg/ml and indicated for the treatment of relapsing forms of Multiple Sclerosis (MS), to include clinically isolated syndrome ...

Early Treatment Of Multiple Sclerosis; Gd+: Gadolinium-enhancing; IM: Intramuscular; NA: Not applicable; PreCISe: Effect of Glatiramer Acetate Treatment in Delaying Conversion to Clinically ...

Zydus Lifesciences receives USFDA approval to market a generic medication for multiple sclerosis, a generic version of Copaxone. The drug will be manufactured in Europe.

Zydus’ generic Glatiramer Acetate Injection is an FDA-approved, AP-rated substitutable generics of Copaxone ® 20 mg/ml, 40 mg/ml and indicated for the treatment of relapsing forms of Multiple ...

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic ...

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis ... Copaxone (glatiramer acetate) patent expired in ...

Zydus’ generic Glatiramer Acetate Injection is an FDA-approved, AP-rated substitutable generics of Copaxone 20 mg/ml, 40 mg/ml and indicated for the treatment of relapsing forms of Multiple Sclerosis ...